image header

Investor Overview

Investor Overview

ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Our lead candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. We have developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities.

ALX Oncology


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

Jul 21, 2020

ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Read more

Jul 16, 2020

ALX Oncology Announces Pricing of Initial Public Offering Read more

Jun 12, 2020

ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Read more

Upcoming Events

Sep 15 - Sep 17, 2020

Cantor Virtual Global Healthcare Conference